Aspen Neuroscience Inc.
Aspen Neuroscience Inc.
Your view on ASPE
Overview
What the company does, where it operates, and who runs it.
About Aspen Neuroscience Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Damien McDevitt
- Headquarters
- 10835 Road to the Cure, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Damien McDevitt
- Headquarters
- 10835 Road to the Cure, San Diego, CA, US
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases.
Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Aspen Neuroscience Inc. from FRC's valuation model, read against the market price. ASPE last traded at $12.01; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Aspen Neuroscience Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Aspen Neuroscience Inc.. Aspen Neuroscience Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Aspen Neuroscience Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Aspen Neuroscience Inc.. Aspen Neuroscience Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
More Biotechnology companies
Market cap
- ZLDAFZelira Therapeutics LimitedOTC$5M
- ZLDPFZealand Pharma A/SOTC$4.0B
- ZNTLZentalis Pharmaceuticals, Inc.NASDAQ$134M
- ZURAZura Bio LimitedNASDAQ$93M
- ZVRAZevra Therapeutics, Inc.NASDAQ$552M
- ZVSAZyVersa Therapeutics, Inc.OTC$1M
- ZYMEZymeworks Inc.NASDAQ$1.8B
- VSBCVitaSpring Biomedical Co. Ltd.OTC$2M
- VSTMVerastem, Inc.NASDAQ$866M
- VTGNVistaGen Therapeutics, Inc.NASDAQ$9M
- VTIAFFamiCord AGOTC$111M
- VTVTvTv Therapeutics Inc.NASDAQ$64M
ETFs holding Aspen Neuroscience Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- VTWOVanguard Russell 2000 ETF$16.6B in assets0.00%
- VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
- VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.00%
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
- VTHRVanguard Russell 3000 ETF$4.9B in assets0.00%
Largest holders first, then the funds most concentrated in ASPE.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Aspen Neuroscience Inc., and how their positions are changing. At a $349.2M market value, institutional positions materially move Aspen Neuroscience Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Aspen Neuroscience Inc. executives and directors. Shares of Aspen Neuroscience Inc. have traded between $11.20 and $14.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Aspen Neuroscience Inc.. Aspen Neuroscience Inc. is a $349.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Aspen Neuroscience Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Aspen Neuroscience Inc.. Coverage tracks Aspen Neuroscience Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Aspen Neuroscience Inc.